Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium

Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir-, raltegravir- or etravirine-containing antiretroviral therapy in the Western Cape Province of South Africa

(2018) J Nuttall et al.   SAMJ SOUTH AFRICAN MEDICAL JOURNAL

Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents

(2017) Wasana Prasitsuebsai et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age

(2015) Matthew L. Rizk et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing

(2014) Diana F. Clarke et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Raltegravir Pharmacokinetics During Pregnancy

(2014) D. Heather Watts et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

(2014) Nicholas I. Paton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years

(2013) S. Nachman et al.   CLINICAL INFECTIOUS DISEASES

Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients

(2011) V Briz et al.   HIV MEDICINE

Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa

(2011) M. Egger et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus

(2009) Isabelle Thuret et al.   AIDS

PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE

(2009) Gert U. van Zyl et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL